Supplementary Material

Table S1. Enrichments of all phenotypes in the Pre-COVID time horizon for 1, 2, and 3 note thresholds. Phenotypes in the hospitalized and non-hospitalized post-clearance cohorts, along with results from statistical significance tests the time period one year prior to up to 11 days prior to the first positive SARS-CoV-2 PCR test for a patient. Features which are significantly different between the two cohorts are highlighted in green. The columns are: (1) Phenotype: phenotype of interest, (2) Minimum distinct positive mentions: Minimum number of distinct mentions in the physician notes with a positive sentiment required to record a phenotype, (3) Hospitalized post-clearance: number of patients in the hospitalized post-clearance cohort with the phenotype recorded in the Pre-COVID time horizon, (4) Non-Hospitalized post-clearance: number of patients in the non-hospitalized post-clearance cohort with the phenotype recorded in the Pre-COVID time horizon, (5) BH-corrected p-value: Benjamani-Hochberg corrected p-values using Fisher Exact test for comparisons of proportions, (6) Relative risk (95% CI): Ratio of the phenotype incidence in the hospitalized post-clearance cohort to the phenotype incidence in the non-hospitalized post-clearance cohort, along with 95% confidence interval bounds.

Phenotype	Minimum distinct positive mentions	Hospitalized Post Clearance (93 patients)	Non-Hospitalized Post-Clearance (173 patients)	BH-corrected p-value	Relative risk (95% CI)
Acute kidney injury	1	15 (16.1%)	7 (4%)	0.03	4 (1.7, 8.8)
Acute kidney injury	2	11 (11.8%)	6 (3.5%)	0.12	3.4 (1.3, 8.3)
Acute kidney injury	3	9 (9.7%)	5 (2.9%)	0.21	3.3 (1.2, 8.9)
Anemia	1	26 (28%)	27 (15.6%)	0.19	1.8 (1.1, 2.9)
Anemia	2	21 (22.6%)	18 (10.4%)	0.12	2.2 (1.2, 3.8)
Anemia	3	20 (21.5%)	12 (6.9%)	0.02	3.1 (1.6, 5.9)
Acute respiratory distress syndrome / acute lung injury	1	3 (3.2%)	4 (2.3%)	1	1.4 (0.36, 5.7)
Acute respiratory distress syndrome / acute lung injury	2	2 (2.2%)	2 (1.2%)	1	1.9 (0.33, 10)
Acute respiratory distress syndrome / acute lung injury	3	2 (2.2%)	2 (1.2%)	1	1.9 (0.33, 10)
Cardiac arrest	1	1 (1.1%)	1 (0.6%)	1	1.9 (0.2, 18)

Cardiac arrest	2	0 (0%)	0 (0%)	1	nan (0.037, 93)
Cardiac arrest	3	0 (0%)	0 (0%)	1	nan (0.037, 93)
Cardiac arrhythmias	1	26 (28%)	32 (18.5%)	0.47	1.5 (0.96, 2.4)
Cardiac arrhythmias	2	21 (22.6%)	24 (13.9%)	0.46	1.6 (0.96, 2.7)
Cardiac arrhythmias	3	21 (22.6%)	17 (9.8%)	0.05	2.3 (1.3, 4.1)
Heart failure	1	8 (8.6%)	10 (5.8%)	1	1.5 (0.63, 3.6)
Heart failure	2	8 (8.6%)	7 (4%)	0.65	2.1 (0.81, 5.4)
Heart failure	3	7 (7.5%)	7 (4%)	0.95	1.9 (0.69, 4.9)
Hyperglycemia	1	7 (7.5%)	22 (12.7%)	0.71	0.59 (0.28, 1.4)
Hyperglycemia	2	6 (6.5%)	13 (7.5%)	1	0.86 (0.36, 2.2)
Hyperglycemia	3	3 (3.2%)	11 (6.4%)	0.95	0.51 (0.17, 1.8)
Hypertension	1	42 (45.2%)	62 (35.8%)	0.6	1.3 (0.93, 1.7)
Hypertension	2	33 (35.5%)	50 (28.9%)	0.87	1.2 (0.86, 1.8)
Hypertension	3	29 (31.2%)	46 (26.6%)	0.95	1.2 (0.8, 1.7)
Myocardial infarction	1	2 (2.2%)	4 (2.3%)	1	0.93 (0.22, 4.7)
Myocardial infarction	2	2 (2.2%)	4 (2.3%)	1	0.93 (0.22, 4.7)
Myocardial infarction	3	1 (1.1%)	3 (1.7%)	1	0.62 (0.12, 5.3)
Pleural effusion	1	7 (7.5%)	12 (6.9%)	1	1.1 (0.47, 2.7)
Pleural effusion	2	6 (6.5%)	10 (5.8%)	1	1.1 (0.45, 2.9)
Pleural effusion	3	5 (5.4%)	7 (4%)	1	1.3 (0.47, 4)
Pulmonary embolism	1	2 (2.2%)	6 (3.5%)	1	0.62 (0.17, 3)
Pulmonary embolism	2	1 (1.1%)	6 (3.5%)	0.98	0.31 (0.074, 2.5)
Pulmonary embolism	3	1 (1.1%)	6 (3.5%)	0.95	0.31 (0.074, 2.5)
Respiratory failure	1	1 (1.1%)	6 (3.5%)	1	0.31 (0.074, 2.5)
Respiratory failure	2	1 (1.1%)	6 (3.5%)	0.98	0.31 (0.074, 2.5)

Respiratory failure	3	1 (1.1%)	5 (2.9%)	1	0.37 (0.084, 3)
Sepsis	1	5 (5.4%)	8 (4.6%)	1	1.2 (0.42, 3.4)
Sepsis	2	4 (4.3%)	5 (2.9%)	1	1.5 (0.45, 5.1)
Sepsis	3	4 (4.3%)	4 (2.3%)	0.95	1.9 (0.51, 6.7)
Septic shock	1	1 (1.1%)	2 (1.2%)	1	0.93 (0.15, 8.3)
Septic shock	2	1 (1.1%)	2 (1.2%)	1	0.93 (0.15, 8.3)
Septic shock	3	1 (1.1%)	1 (0.6%)	1	1.9 (0.2, 18)
Stroke / Cerebrovascular incident	1	0 (0%)	3 (1.7%)	1	0 (0.014, 5.1)
Stroke / Cerebrovascular incident	2	0 (0%)	3 (1.7%)	1	0 (0.014, 5.1)
Stroke / Cerebrovascular incident	3	0 (0%)	1 (0.6%)	1	0 (0.025, 15)
Venous thromboembolism / deep vein thrombosis	1	4 (4.3%)	6 (3.5%)	1	1.2 (0.4, 4.2)
Venous thromboembolism / deep vein thrombosis	2	3 (3.2%)	4 (2.3%)	1	1.4 (0.36, 5.7)
Venous thromboembolism / deep vein thrombosis	3	3 (3.2%)	4 (2.3%)	1	1.4 (0.36, 5.7)